AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 281
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and calcium-channel blockers
Number of subjects: 281
Study 10730357 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with elastic lumbar belts
Number of subjects: 97
Study 10730357 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group without elastic lumbar belts
Number of subjects: 97
Study 10730357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 97
Study 10730357 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with elastic lumbar belts (low back pain patients)
Number of subjects: 97
Study 10730357 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group without elastic lumbar belts (low back pain patients)
Number of subjects: 97
Study 10730357 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with elastic lumbar belts (healthy backs)
Number of subjects: 97
Study 10730357 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy backs)
Number of subjects: 97
Study 9172188 — intervention group
Group type: EXPERIMENTAL
Intervention: telic-low arousal
Number of subjects: 28
Study 9172188 — intervention group
Group type: EXPERIMENTAL
Intervention: paratelic-low arousal
Number of subjects: 28
Study 9172188 — intervention group
Group type: EXPERIMENTAL
Intervention: telic-high arousal
Number of subjects: 28
Study 9172188 — intervention group
Group type: EXPERIMENTAL
Intervention: paratelic-high arousal
Number of subjects: 28
Study 9172188 — intervention group
Group type: EXPERIMENTAL
Intervention: combined high (telic-low, paratelic-high)
Number of subjects: 28
Study 9172188 — intervention group
Group type: EXPERIMENTAL
Intervention: combined low (telic-low, paratelic-high)
Number of subjects: 28
Study 8336912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinoscopy
Number of subjects: 57
Study 8336912 — intervention group
Group type: COMPARATOR
Intervention: Subjective push-up method
Number of subjects: 57
Study 8336912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinoscopy by four other examiners
Number of subjects: 57
Study 2873176 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing multi-layer operating room masks during visits to patient rooms
Number of subjects: 0
Study 2873176 — intervention group
Group type: COMPARATOR
Intervention: Control group (not wearing masks)
Number of subjects: 0
Study 29097499 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose lenalidomide (n=15)
Number of subjects: 88
Study 29097499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential azacitidine and lenalidomide (n=39)
Number of subjects: 88
Study 29097499 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine only (n=34)
Number of subjects: 88
Study 27655756 — intervention group
Group type: EXPERIMENTAL
Intervention: High egg (HE) - 150 g cooked egg
Number of subjects: 16
Study 27655756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low egg (LE) - 75 g cooked egg
Number of subjects: 16
Study 27655756 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - no egg
Number of subjects: 16
Study 24112439 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reaching action
Number of subjects: 3
Study 24112439 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful reaching action
Number of subjects: 3
Study 22430266 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo‐oophorectomy (RRSO)
Number of subjects: 964
Study 22430266 — intervention group
Group type: EXPERIMENTAL
Intervention: 6174delT mutation
Number of subjects: 964
Study 22430266 — intervention group
Group type: COMPARATOR
Intervention: RRSO
Number of subjects: 964
Study 20799930 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Art Therapy plus standard care
Number of subjects: 0
Study 20799930 — intervention group
Group type: COMPARATOR
Intervention: Attention control 'activity' group plus standard care
Number of subjects: 0
Study 20799930 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 18263672 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmethylphenidate hydrochloride (d‐MPH)
Number of subjects: 10
Study 18263672 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 15719193 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-side stapled anastomosis
Number of subjects: 122
Study 15719193 — intervention group
Group type: COMPARATOR
Intervention: Handsewn end-to-end anastomosis
Number of subjects: 122
Study 12480610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg twice a day plus montelukast 10 mg at night for 8 weeks
Number of subjects: 28
Study 12480610 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg twice a day
Number of subjects: 28
Study 10585054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonheparin‐bonded circuit with no albumin preprime
Number of subjects: 200
Study 10585054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonheparin‐bonded circuit with albumin preprime
Number of subjects: 200
Study 10585054 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐bonded circuit with no albumin preprime
Number of subjects: 200
Study 10585054 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐bonded circuit with albumin preprime
Number of subjects: 200
Study 8933763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy in one eye
Number of subjects: 1242
Study 8933763 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (no cryotherapy)
Number of subjects: 1242
Study 8933763 — intervention group
Group type: COMPARATOR
Intervention: Natural History cohort (no specific intervention)
Number of subjects: 1242
Study 1910228 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (2.4 million units) and procaine penicillin (2.0 million units) intramuscularly
Number of subjects: 320
Study 1910228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 320
Study 1910228 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin and procaine penicillin for wounds repaired nine or more hours after injury
Number of subjects: 320
Study 1910228 — intervention group
Group type: COMPARATOR
Intervention: Control group for wounds repaired nine or more hours after injury
Number of subjects: 320
Study 1910228 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin and procaine penicillin for wounds involving the head or repaired within nine hours
Number of subjects: 320
Study 1910228 — intervention group
Group type: COMPARATOR
Intervention: Control group for wounds involving the head or repaired within nine hours
Number of subjects: 320
Study 7221401 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provision of bath aids and instruction by a peripatetic occupational therapist
Number of subjects: 100
Study 7221401 — intervention group
Group type: COMPARATOR
Intervention: Usual channels for receiving bath aids
Number of subjects: 100
Study 30759035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 20 mg BD (12-hourly)
Number of subjects: 20
Study 30759035 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg OD (once-daily)
Number of subjects: 20
Study 29291771 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus faecium strain SF68 (SF68)
Number of subjects: 27
Study 29291771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29291771 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate
Number of subjects: 27
Study 28011811 — intervention group
Group type: EXPERIMENTAL
Intervention: safetxt intervention
Number of subjects: 200
Study 28011811 — intervention group
Group type: COMPARATOR
Intervention: Control text messages
Number of subjects: 200
Study 25071063 — intervention group
Group type: EXPERIMENTAL
Intervention: Accupedo‐Pro Pedometer app
Number of subjects: 12
Study 21487115 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person perspective
Number of subjects: 0
Study 21487115 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person perspective
Number of subjects: 0
Study 21487115 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-change
Number of subjects: 0
Study 21487115 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective shifting
Number of subjects: 0
Study 18642636 — intervention group
Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS) therapy
Number of subjects: 12
Study 16564860 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 247
Study 13679496 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks (Group A)
Number of subjects: 21
Study 13679496 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 8 weeks (Group B)
Number of subjects: 21
Study 10735395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg twice per day for 7 days (n = 128)
Number of subjects: 255
Study 10735395 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (n = 127)
Number of subjects: 255
Study 10735395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 255
Study 10735395 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 255
Study 8827132 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 0
Study 8827132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1420504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LDAC) 10 mg/m2 subcutaneously BID
Number of subjects: 141
Study 1420504 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 141
Study 3880775 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenylalanine intake (900-4000 microM)
Number of subjects: 10
Study 3880775 — intervention group
Group type: COMPARATOR
Intervention: Low phenylalanine intake
Number of subjects: 10
Study 3880775 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenylalanine intake
Number of subjects: 10
Study 30837258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 16
Study 30837258 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTOCLO (PENtoxifylline+TOcopherol±CLOdronate)
Number of subjects: 16
Study 28145050 — intervention group
Group type: COMPARATOR
Intervention: CYP2B6 516 G/G genotype
Number of subjects: 191
Study 28145050 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 516 T allele carriers
Number of subjects: 191
Study 25946280 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary-vein isolation alone
Number of subjects: 589
Study 25946280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary-vein isolation plus ablation of complex fractionated electrograms
Number of subjects: 589
Study 25946280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary-vein isolation plus linear ablation
Number of subjects: 589
Study 23475377 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisting force (AF) group
Number of subjects: 0
Study 23475377 — intervention group
Group type: EXPERIMENTAL
Intervention: Repelling force (RF) group
Number of subjects: 0
Study 23475377 — intervention group
Group type: COMPARATOR
Intervention: Control (CT) group
Number of subjects: 0
Study 21494105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subclavian vein cannulation
Number of subjects: 463
Study 21494105 — intervention group
Group type: COMPARATOR
Intervention: Landmark method
Number of subjects: 463
Study 19609105 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a low dose (3 microg/kg/day)
Number of subjects: 86
Study 19609105 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a conventional dose (6 microg/kg/day)
Number of subjects: 86
Study 19609105 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at both doses
Number of subjects: 86
Study 16505299 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support on a treadmill (BWSTT)
Number of subjects: 146
Study 16505299 — intervention group
Group type: COMPARATOR
Intervention: Defined over-ground mobility therapy (CONT)
Number of subjects: 146
Study 16505299 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support on a treadmill (BWSTT) and Defined over-ground mobility therapy (CONT)
Number of subjects: 146
Study 12620436 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen therapy (newly initiated estrogen patch)
Number of subjects: 40
Study 12620436 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal estrogen therapy
Number of subjects: 40
Study 12620436 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 40
Study 10710064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxil (900 ml)
Number of subjects: 28
Study 10710064 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-contrast MRI (ferumoxil and gadolinium)
Number of subjects: 28
Study 10710064 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 controls for each intervention)
Number of subjects: 28
Study 9093935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 400 micrograms/day for 4 weeks
Number of subjects: 0
Study 9093935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 800 micrograms/day for 4 weeks
Number of subjects: 0
Study 9093935 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone, 1 mg/kg/day for 2 weeks
Number of subjects: 0
Study 1540019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 ml daily)
Number of subjects: 86
Study 1540019 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo (10 ml daily)
Number of subjects: 86
Study 3457524 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg four times daily)
Number of subjects: 30
Study 3457524 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg four times daily)
Number of subjects: 30
Study 3457524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 89
Study 30111466 — intervention group
Group type: COMPARATOR
Intervention: Heated humidified high flow nasal cannula (HHHFNC)
Number of subjects: 89
Study 27710100 — intervention group
Group type: EXPERIMENTAL
Intervention: UV ink tattoos
Number of subjects: 46
Study 27710100 — intervention group
Group type: COMPARATOR
Intervention: Conventional dark ink tattoos
Number of subjects: 46
Study 24885324 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Shen Jian Gu granules
Number of subjects: 0
Study 24885324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22257943 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland's passive accessory mobilization
Number of subjects: 28
Study 22257943 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 28
Study 19995932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 51
Study 18625629 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA treatment comprising sulfasalazine, methotrexate and high‐dose step‐down prednisolone, intensified by adding hydroxychloroquine and continued low‐dose prednisolone
Number of subjects: 21
Study 18625629 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group for CTX‐II
Number of subjects: 21
Study 16572123 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 250 microg/kg
Number of subjects: 20
Study 16572123 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 500 microg/kg
Number of subjects: 20
Study 16572123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 microg/kg THC)
Number of subjects: 20
Study 12679450 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone (up to 45 mg for 77% of patients)
Number of subjects: 205
Study 12679450 — intervention group
Group type: COMPARATOR
Intervention: 850 mg metformin (up to 2550 mg for 73% of patients)
Number of subjects: 205
Study 12679450 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 205
Study 12679450 — intervention group
Group type: COMPARATOR
Intervention: 850 mg metformin
Number of subjects: 205
Study 10889818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus antigen ELISA
Number of subjects: 104
Study 10889818 — intervention group
Group type: COMPARATOR
Intervention: Latex agglutination (LA) test
Number of subjects: 104
Study 8770436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment group: 8 weeks with a self-care manual followed by up to eight sessions of CBT if still symptomatic.
Number of subjects: 110
Study 8770436 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group: 16 sessions of CBT.
Number of subjects: 110
Study 8770436 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care manual (part of the sequential treatment).
Number of subjects: 110
Study 8770436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment group.
Number of subjects: 110
Study 1593057 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily for 6 months
Number of subjects: 197
Study 1593057 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 197
Study 1593057 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily
Number of subjects: 197
Study 1593057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 6323667 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment) applied four times a day for 7 days
Number of subjects: 102
Study 6323667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 6323667 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment)
Number of subjects: 102
Study 31420274 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid levels in the 3rd tertile (≥327 μmol/L)
Number of subjects: 191
Study 31420274 — intervention group
Group type: EXPERIMENTAL
Intervention: High uric acid levels (≥327 μmol/L)
Number of subjects: 191
Study 31420274 — intervention group
Group type: EXPERIMENTAL
Intervention: High modified Rankin Scale score
Number of subjects: 191
Study 31420274 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 191
Study 29409923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot snare polypectomy (HSP)
Number of subjects: 269
Study 27734491 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth closed
Number of subjects: 10
Study 27734491 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth open
Number of subjects: 10
Study 27734491 — intervention group
Group type: COMPARATOR
Intervention: Face mask oxygenation at 10 l.min‐1
Number of subjects: 10
Study 24670704 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced decrease in CXCL10 levels in patients with 'insufficient' and 'deficient' vitamin D levels.
Number of subjects: 0
Study 24670704 — intervention group
Group type: COMPARATOR
Intervention: CXCL10 levels in patients with 'optimal' vitamin D levels.
Number of subjects: 0
Study 23241929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lady Prelox
Number of subjects: 83
Study 23241929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 20695797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MM) supplementation
Number of subjects: 287
Study 20695797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 17506789 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 251
Study 17506789 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 251
Study 15849477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 160
Study 12468337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal mitoxantrone
Number of subjects: 31
Study 12468337 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal fluorodeoxyuridine (FUDR)
Number of subjects: 31
Study 10086702 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F alpha-methyl tyrosine (FMT) PET imaging
Number of subjects: 31
Study 7677556 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy information distributed before the day of admission
Number of subjects: 419
Study 7677556 — intervention group
Group type: COMPARATOR
Intervention: Proxy information distributed only on the day of admission
Number of subjects: 419
Study 2183111 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 30
Study 2183111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block
Number of subjects: 30
Study 2183111 — intervention group
Group type: COMPARATOR
Intervention: Unanesthetized control
Number of subjects: 30
Study 6265162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (3 h) before surgery for 4 days
Number of subjects: 70
Study 6265162 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 70
Study 30883233 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel
Number of subjects: 100
Study 30883233 — intervention group
Group type: COMPARATOR
Intervention: No topical agent
Number of subjects: 100
Study 29156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (RT) with a single 8 Gy dose
Number of subjects: 107
Study 29156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants (SNVs) identified through saliva sequencing
Number of subjects: 107
Study 29156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific SNVs (e.g., AOAH rs7986, ZAN rs539445, RAG1 rs3740955)
Number of subjects: 107
Study 29156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion at position 111992032 in the ataxin gene ATXN2
Number of subjects: 107